Gilead, Cipla Lose Bid to End Health Plan’s Suit Over HIV Drugs

Gilead Sciences Inc. and Cipla Ltd. must face antitrust litigation over their alleged scheme to delay generic versions of Gilead’s blockbuster HIV drugs through illegal patent settlements, a federal judge in Oakland, Calif., ruled, though he did trim part of the case.

Judge Jeffrey S. White let the lawsuit move forward with claims that Gilead effectively paid Cipla to stay out of the market for Truvada and related medications through secret settlement terms, including a license worth up to $185 million to manufacture the active ingredient of an unrelated hepatitis C drug.

The judge cited allegations that a global settlement ...